Medicover

+36 1 465 3100

info@medicover.hu

pca3

PROGENSA ™ PCA3 test

E-mail

PROGENSA ™ PCA3 test

Why do we recommend it?

• GENETICALLY BASED HELP IN BIOPSY DECISIONS
• SIMPLE SAMPLING (first urine after DRE)
 

Prostate cancer is the fourth most frequent malignant disease of men in Hungary. An average of 2,400 new patients are diagnosed each year and 1,400 men die of the disease annually.

According to current practices, prostate biopsies are performed depending on the results of the PSA (fPSA) test and the digital rectal examination (DRE).

Prostate cancer is diagnosed in about 23% of the biopsy specimens. That unfortunately means that 77% of biopsies are performed unnecessarily, which means significant extra healthcare costs, as well as discomfort and possible complications for the patients.

The test is the currently available most specific molecular biological test in the detection of prostate cancer.

The testing process

The PCA assay is performed form the first urine sample after the DRE performed by the urologist.

The result.

The result of the test is the so-called PCA3-value, which predicts the biopsy result in 80% of the cases.

Price:

Please report through our Call Center for the urological examination to obtain the urine sample taken after DRE, which is necessary for the PCA assay.

REQUEST A QUOTE


*Our prices concern to Medicover Clinics in Budapest.